1PK Stock Overview Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Dechra Pharmaceuticals PLC Competitors Price History & Performance
Summary of share price highs, lows and changes for Dechra Pharmaceuticals Historical stock prices Current Share Price UK£44.40 52 Week High UK£45.20 52 Week Low UK£28.00 Beta 0.78 1 Month Change 0.45% 3 Month Change 2.30% 1 Year Change 35.37% 3 Year Change 9.25% 5 Year Change 65.18% Change since IPO 272.64%
Recent News & Updates Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 20
Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 18
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million. Apr 12 Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director
EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH). Jan 17 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP) See more updates Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 20
Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 18
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million. Apr 12 Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director
EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH). Jan 17 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)
Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024 Dec 27
Dechra Pharmaceuticals Plc Announces Directorate Change Nov 29
Dechra Pharmaceuticals Plc Announces Directorate Change Nov 28
Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023 Sep 27 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director Jun 17
Dechra Pharmaceuticals Intends to Delist from Official List Jun 03
Investor sentiment improves as stock rises 33% Apr 13
First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022) Feb 28
Investor sentiment improved over the past week Jan 14
Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company Dec 21
Now 20% undervalued after recent price drop Dec 21
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index Dec 19
Less than half of directors are independent Nov 16
Upcoming dividend of UK£0.33 per share Oct 20 Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023
Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021) Sep 06
Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022 Sep 05
Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis. Aug 31 Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.
Now 22% undervalued after recent price drop Jun 14
Dechra Pharmaceuticals PLC Announces Executive Changes May 18
Now 21% undervalued after recent price drop May 07
Less than half of directors are independent Apr 27
Non-Executive Chairman recently bought €119k worth of stock Apr 09
Upcoming dividend of UK£0.12 per share Feb 24
First half 2022 earnings: Revenues and EPS in line with analyst expectations Feb 22
Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022 Feb 22
Dechra Pharmaceuticals plc Announces Executive Changes Feb 17
Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc. Jan 12 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
Non-Executive Director Denise Goode has left the company Dec 01
Upcoming dividend of UK£0.29 per share Oct 21
Upcoming dividend of UK£0.29 per share Oct 21
Board Member recently sold €1.0m worth of stock Sep 15
Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020) Sep 08
Board Member recently sold €1.1m worth of stock Apr 17
First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020) Feb 23
Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C Feb 10
New 90-day high: €41.36 Feb 09 Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021
New 90-day high: €38.84 Jan 12
CEO, MD & Executive Director recently sold €12m worth of stock Nov 22
Dechra Pharmaceuticals PLC Launches Mirataz Nov 10
Upcoming Dividend of UK£0.24 Per Share Oct 29
Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021 Oct 27
New 90-day high: €38.52 Oct 15
Non-Executive Director recently bought €28k worth of stock Oct 10
Non-Executive Director recently bought €28k worth of stock Oct 08
Independent Non Executive Director recently sold €142k worth of stock Sep 20
Full year earnings released - EPS €0.33 Sep 09
New 90-day high - €36.48 Aug 27
New 90-day high - €33.70 Aug 06
New 90-day high - €32.96 Jul 20 Shareholder Returns 1PK DE Pharmaceuticals DE Market 7D -0.4% -2.2% -2.0% 1Y 35.4% -15.8% 6.8%
See full shareholder returns
Return vs Market: 1PK exceeded the German Market which returned -1.1% over the past year.
Price Volatility Is 1PK's price volatile compared to industry and market? 1PK volatility 1PK Average Weekly Movement 2.8% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1PK has not had significant price volatility in the past 3 months.
Volatility Over Time: 1PK's weekly volatility (3%) has been stable over the past year.
About the Company Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases.
Show more Dechra Pharmaceuticals PLC Fundamentals Summary How do Dechra Pharmaceuticals's earnings and revenue compare to its market cap? 1PK fundamental statistics Market cap €5.11b Earnings (TTM ) -€32.39m Revenue (TTM ) €884.12m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1PK income statement (TTM ) Revenue UK£761.50m Cost of Revenue UK£331.90m Gross Profit UK£429.60m Other Expenses UK£457.50m Earnings -UK£27.90m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -0.24 Gross Margin 56.42% Net Profit Margin -3.66% Debt/Equity Ratio 64.6%
How did 1PK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/01/16 22:33 End of Day Share Price 2024/01/16 00:00 Earnings 2023/06/30 Annual Earnings 2023/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Dechra Pharmaceuticals PLC is covered by 21 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Samuel England Berenberg Laurent Gelebart BNP Paribas Exane Brian White Cantor Fitzgerald Europe
Show 18 more analysts 
